Prof. Jianji Pan 潘建基
Chief Physician, Professor
Department of Radiation Oncology, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation oncology, with a focus on head and neck tumors, brachytherapy, and 3D intensity-modulated conformal radiation therapy.
Dr. Pan earned an MD from Fujian Medical University in 1982 and a medical doctorate from the University of Nancy I, France, in 1990. As Vice President and Chief Physician at Fujian Cancer Hospital, Dr. Pan specializes in precise radiation techniques for head and neck cancers. Dr. Pan has published over 50 papers and monographs and received the Fujian Provincial Science and Technology Progress Award.
Professional roles
- Vice Chair, Radiation Oncology Branch, Chinese Medical Association
- Leader, Nasopharyngeal Carcinoma Group, Radiation Oncology Branch, Chinese Medical Association
- Standing Committee Member, Professional Committee on Tumor Radiotherapy, China Anti-Cancer Association
- Vice Chair, Professional Committee on Nasopharyngeal Carcinoma, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Pan Jianji). Papers usually list the name as Jianji Pan or Pan J.
Selected publications
89 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- JAMA Oncol, 2024 (first author): Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification. PubMed 39388190
- Radiat Oncol, 2022 (senior author): Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma. PubMed 35790987
- Oncologist, 2022 (senior author): Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma. PubMed 35380720
- Cancer Sci, 2020 (senior author): Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma. PubMed 32155300
- Cancer Med, 2020 (senior author): Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma. PubMed 32090498
- Onco Targets Ther, 2020 (senior author): High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma. PubMed 32161471
- Oral Oncol, 2019 (senior author): Prognostic value of radiologic extranodal extension and its potential role in future N classification for nasopharyngeal carcinoma. PubMed 31654937
- Head Neck, 2019 (senior author): Prognosis of nasopharyngeal carcinoma with insufficient radical dose to the primary site in the intensity-modulated radiotherapy era. PubMed 31313419
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion